Recent studies have demonstrated cyclooxygenase 2 (COX-2) overexpression in various human malignancies, especially in breast cancer, where COX-2 turned out to be a predictor of poor survival. To evaluate the relation of COX-2 and Ep-CAM overexpression and its prognostic significance, we performed a retrospective study on 212 breast cancer patients with a median follow-up time of 10.5 years. Overexpression of COX-2 in tumour tissue samples was assessed by immunohistochemistry. COX-2 overexpression was found in 48.6% of the tumour samples and was predictive for poor disease-free and overall survival. Univariate analysis revealed a strong correlation between COX-2 and Ep-CAM overexpression (P ¼ 0.009). Concurrent COX-2 and Ep-CAM overexpression was present in 21.7% of tumour specimens and had an additive negative impact on disease-free and overall survival. Determination of both tumour markers should help in guiding new therapeutic strategies in patients with invasive breast cancer. Cyclooxygenase-2 (COX-2) is a prostaglandin synthase that catalyses the synthesis of prostaglandin G 2 (PGG 2 ) and PGH 2 from arachidonic acid. Recent studies have led to the recognition of the importance of COX-2 in tumorigenesis of different tumour types. It has been shown that COX-2 is involved in tumour angiogenesis (Tsujii et al, 1998; Gately, 2000) , in suppression of apoptosis (Sheng et al, 1998) and in the promotion of invasiveness (Tsujii et al, 1997) . COX-2 overexpression was found in pancreatic (Molina et al, 1999; Okami et al, 1999; Kokawa et al, 2001) , oesophageal (Zimmermann et al, 1999) , prostate (Yoshimura et al, 2000) , lung (Khuri et al, 2001) , head and neck cancers (Chan et al, 1999) and in malignant gliomas (Shono et al, 2001) . Tsujii et al reported that COX-2 overexpression in intestinal epithelial cells leads to downregulation of adhesion molecules (i.e. cadherins), resulting in an enhanced tumorigenic potential (Tsujii and DuBois, 1995) .
Cyclooxygenase-2 (COX-2) is a prostaglandin synthase that catalyses the synthesis of prostaglandin G 2 (PGG 2 ) and PGH 2 from arachidonic acid. Recent studies have led to the recognition of the importance of COX-2 in tumorigenesis of different tumour types. It has been shown that COX-2 is involved in tumour angiogenesis (Tsujii et al, 1998; Gately, 2000) , in suppression of apoptosis (Sheng et al, 1998) and in the promotion of invasiveness (Tsujii et al, 1997) . COX-2 overexpression was found in pancreatic (Molina et al, 1999; Okami et al, 1999; Kokawa et al, 2001) , oesophageal (Zimmermann et al, 1999) , prostate (Yoshimura et al, 2000) , lung (Khuri et al, 2001) , head and neck cancers (Chan et al, 1999) and in malignant gliomas (Shono et al, 2001 ). Tsujii et al reported that COX-2 overexpression in intestinal epithelial cells leads to downregulation of adhesion molecules (i.e. cadherins), resulting in an enhanced tumorigenic potential (Tsujii and DuBois, 1995) .
Enhanced COX-2 expression in breast cancer was first indicated by reports of elevated prostaglandin levels in breast carcinomas (Bennett et al, 1977) , particularly in patients with metastatic disease (Rolland et al, 1980) . A key role of COX-2 for the initiation and progression of breast cancer is suggested by the finding that mere overexpression of COX-2 can be sufficient for inducing mammary gland tumorigenesis in transgenic mice (Liu et al, 2001) . Notably, in human breast cancer cell lines, a positive correlation was found between invasiveness, metastatic potential and prostaglandin production (Liu and Rose, 1996) . Different groups have described the prognostic significance of COX-2 overexpression in breast cancer (Hwang et al, 1998; Ristimaki et al, 2002; Soslow et al, 2000) .
We have recently described the prognostic significance of Ep-CAM overexpression in patients with invasive breast cancer (Gastl et al, 2000) . Ep-CAM (also called 17-1A, ESA, EGP40, 323/A3) is a 40-kDa transmembrane glycoprotein expressed on most human epithelial cells (Gottlinger et al, 1986) . The Ep-CAM glycoprotein functions as a homotypic intercellular adhesion molecule (Litvinov et al, 1994) and has become a target for antibody-mediated immunotherapy with the murine monoclonal antibody edrecolomab (Riethmuller et al, 1998) . So far, no data have been reported on the correlation of COX-2 overexpression with Ep-CAM overexpression in human breast cancer. We therefore examined COX-2 and Ep-CAM overexpression in tumour specimens from 212 patients with invasive breast cancer, and analysed the prognostic value of both tumour markers. was 54.2 years (range, 29 -85 years). Patients younger than 50 years were considered premenopausal. Of the women, 112 (52.8%) were node-positive and 100 (47.2%) node-negative. After primary surgery the clinical status was documented by re-evaluating each patient at least once annually at the Department of Surgery. The evaluation procedure included physical examination, mammography, abdominal ultrasound and chest radiography. The median follow-up time was 10.5 years (range, 36 -240 months) . During this observation period 96 patients relapsed. Of a total of 94 deaths, 84 were due to breast cancer, while 10 patients died without documented disease recurrence.
Histopathology
All tumour samples were formalin-fixed, embedded in paraffin wax and stored at the local pathology repository. Haematoxylinand eosin-stained slides were prepared from each tumour specimen using routine methods and then examined by light microscopy. Histologic type and tumour grade were assessed by one co-author (PO) in a blinded fashion using standard pathology criteria.
Immunohistochemistry
COX-2 overexpression was determined by immunohistochemistry using the murine monoclonal antibody COX-2 (Cayman, USA). Briefly, 5-mm sections were cut from paraffin-embedded tissue blocks, mounted on adhesive-coated glass slides, deparaffinised and rehydrated. Endogenous peroxidase was inactivated by immersing the slides in 0.3% H 2 O 2 in absolute methanol for 20 min at room temperature. Pretreatment consisted of a 15-min incubation period in a water bath at 901C. After washing in Tris buffer, slides were incubated for 2 h with the primary antibody (COX-2, Cayman, USA, dilution 1 : 100). Afterwards, a peroxidaseconjugated goat anti-mouse antibody ready-to-use (EnVisiont, DAKO, Vienna, Austria) was added for 30 min. For immunostaining, slides were then placed into the chromogen consisting of a diaminobenzidine solution. Finally, slides were counterstained with Mayer's Hemalum solution. In addition, slides were immunostained for Ep-CAM essentially as described previously (Gastl et al, 2000; Spizzo et al, 2002) .
Evaluation of slides
COX-2 overexpression was evaluated by two independent assessors (GS and PO) using light microscopy. Reading of tissue slides was blinded, and both assessors were unaware of clinical outcome. COX-2 expression was defined as the presence of specific staining in the cytoplasm of tumour cells. A final expression score was calculated for each tissue sample by multiplying a staining intensity score (0, negative; 1, weak; 2, moderate; 3, strong staining) with a proportion score of positively stained cells (1, 1 -10%; 2, 11 -50%; 3, 50 -80%; 4, 80 -100 %). Only samples with a final expression score 44 were defined as 'overexpressing'. Ep-CAM overexpression was evaluated as previously reported (Gastl et al, 2000; Spizzo et al, 2002) .
Statistical methods
Statistical analysis was performed with the SPSS software program for Windowst. The primary end points in this study were diseasefree and overall survival. Thus, survival curves were calculated according to the method of Kaplan and Meier. P-values were evaluated using the log-rank test for censored survival data. COX-2 and Ep-CAM in human breast cancer G Spizzo et al COX-2 and Ep-CAM overexpression and established prognostic markers, these variables were subjected to multivariate analysis (Cox regression).
RESULTS
In normal mammary epithelium COX-2 showed absent to weak staining ( Figure 1B ). COX-2 overexpression in tumour tissue ( Figure 1A ) was found in 103 of 212 (48.6%) tumour specimens and correlated with poor disease-free (P ¼ 0.02, Figure 2A ) and overall survival (P ¼ 0.04, Figure 2B ). Remarkably, COX-2 overexpression was significantly correlated with Ep-CAM overexpression (Po0.009; w 2 test), histologic tumour type (P ¼ 0.011) and menopausal status (p ¼ 0.047) but failed to correlate with Her-2/ neu status or other tumour parameters (Table 1 ). In 46 (21.7%) of the tumour specimens overexpression of both COX-2 and Ep-CAM was found, while 79 (37.3%) showed neither COX-2 nor Ep-CAM overexpression. Further, three distinct subgroups were identified by the expression of COX-2 and Ep-CAM antigens ( Figure 3A, B) . Patients with tumours overexpressing both antigens carried the poorest prognosis. Median disease-free and median overall survival time in this patient population were 55 months and 90 months, respectively. Patients overexpressing either COX-2 or Ep-CAM had an intermediate prognosis with a median time to relapse of 127 months and a median survival time of 147 months. Finally, patients without overexpression of COX-2 and Ep-CAM in their tumours carried the best prognosis. Median time to relapse and median survival time for this patient group were not reached. By subgroup analysis, overexpression of COX-2 in node-positive cases predicted a dismal prognosis regarding disease-free and overall survival, whereas in node-negative cases COX-2 overexpression was of no prognostic value (data not shown). By multivariate analysis, nodal status, Ep-CAM overexpression, tumour size and histologic grade, but not COX-2 overexpression, proved to be independent prognostic variables for overall survival. For diseasefree survival, nodal status, tumour size and Ep-CAM overexpression, but not COX-2 overexpression, were independent prognostic factors ( Table 2 ).
DISCUSSION
Our study on 212 patients with invasive breast cancer confirms previous reports that COX-2 overexpression is rather frequent in Unknown cases are excluded from P-value calculation. NE=not evaluable. COX-2 overexpression was significantly correlated with Ep-CAM overexpression, histologic tumour type and menopausal status, but failed to correlate with other tumour parameters.
COX-2 and Ep-CAM in human breast cancer G Spizzo et al this patient population (Soslow et al, 2000) and predicts a dismal prognosis for breast cancer patients (Ristimaki et al, 2002) . In experimental studies, COX-2 expression was related to local tumour invasiveness and metastatic potential (Tsujii et al, 1997) . It has recently been demonstrated that COX-2 enhances angiogenesis, an effect that can be blocked by selective COX-2 inhibitors . Thus, COX-2 overexpression may provide a clinically useful biomarker for estimating tumour aggressiveness and patients' prognosis.
In our series, COX-2 overexpression was found to be absent in normal mammary gland epithelium surrounding malignant tissue. This observation is in keeping with recent data showing frequently higher COX-2 expression in various epithelial neoplasia compared with adjacent normal tissue (Soslow et al, 2000; Ristimaki et al, 2002) .
Ep-CAM expression was found to correlate with cell proliferation and dedifferentiation in epithelial cells (de Boer et al, 1999) . To date, little is known about the molecular mechanisms responsible for the regulation of the Ep-CAM gene. The highly significant association of COX-2 and Ep-CAM overexpression suggests a linkage between COX-2 and Ep-CAM signalling. Indeed, Tsujii and DuBois (1995) demonstrated that COX-2 can disrupt cell adhesion mediated by cadherins. Downregulation of cadherins in turn can upregulate Ep-CAM expression. Moreover, cytokines such as IFNa have been shown to upregulate both COX-2 and Ep-CAM expression in epithelial tumour cells (Bostrom et al, 2001; Flieger et al, 2001) . Notably, no correlation was found between Her-2/neu and COX-2 overexpression. This finding is somewhat unexpected, since at least in colorectal cells, COX-2 can be upregulated by Her-2/neu receptor signalling (Vadlamudi et al, 1999) . Taken together, upon validation in prospective studies, the combination of COX-2 and Ep-CAM expression may significantly improve the estimation of breast cancer prognosis. Beside this, COX-2 and Ep-CAM expression have come into focus as novel targets for therapeutic interventions in colorectal cancer. It remains to be seen whether COX-2 inhibitors and Ep-CAM directed monoclonal antibodies turn out to be efficacious for the treatment of other epithelial cancers such as breast carcinoma. 
